25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had previously only been distributed under the Health Canada Special Access Program. 

Gleolan is a 5-aminolevulinic acid hydrochloride powder for oral solution, and is indicated as an adjunct for the visualization of malignant tissue during surgery in patients with grades III or IV gliomas (suspected on preoperative imaging) as classified by the World Health Organization.

Read Medexus Pharmaceuticals press release